• 哈爾濱醫(yī)科大學附屬第四醫(yī)院普外科（哈爾濱150001）;

目的 　探討生存素（survivin）反義核酸（anti-pcDNA3-svv）對胃癌細胞SGC7901的凋亡誘導，對泰索帝的化療增敏作用及降低多藥耐藥基因-1（MDR-1）表達的作用。
方法 　采用脂質(zhì)體法轉(zhuǎn)染SGC7901細胞,并篩選陽性克隆，Western blot檢測survivin蛋白的表達，RT-PCR檢測 MDR-1 mRNA的表達，透射電鏡觀察轉(zhuǎn)染后對SGC7901細胞的凋亡誘導作用，MTT法檢測轉(zhuǎn)染細胞對泰索帝的敏感性。
結(jié)果 　survivin蛋白的表達在重組質(zhì)粒組比空質(zhì)粒組和空白對照組明顯降低（P＜0.05），重組質(zhì)粒組MDR-1 mRNA表達也較其他2組明顯降低（P＜0.01）； 透射電鏡下可見重組質(zhì)粒組細胞呈凋亡晚期變化，其MDR指數(shù)為0.196±0.013，明顯低于空質(zhì)粒組的2.958±0.024和空白對照組的3.126±0.019（P＜0.01）； 重組質(zhì)粒組對泰索帝的IC50值為（16.7±1.98） ng/ml,也明顯低于空質(zhì)粒組的（49.9±1.21） ng/ml和空白對照組的(55.7±1.89) ng/ml（P＜0.01）。
結(jié)論 　survivin反義核酸可誘導SGC7901細胞凋亡，增強泰索帝化療敏感性，可能逆轉(zhuǎn)耐藥。

引用本文： 陳曦海,張豈凡,馬榮. 反義survivin誘導胃癌SGC7901細胞凋亡及逆轉(zhuǎn)耐藥的研究. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(1): 63-67. doi: 復制

1. 　姚學權(quán)， 劉福坤， 祁曉萍， 等. 胃腺癌組織survivin基因的表達與細胞增殖及凋亡的相關(guān)性研究 [J]. 中華外科雜志， 2004； 42（3）∶145.
2. 　Trieb K, Lehner R, Stulnig T, et al. Survivin expression in human osteosarcoma is a marker for survival [J]. Eur J Surg Oncol， 2003; 29(4)∶379.
3. 　Chen LT, Liu TW, Wu CW, et al. A phase Ⅰ study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer [J]. Oncology， 2002; 63(3)∶239.
4. 　Suzuki T, Yoshida K, Tanabe K, et al. Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1 [J]. Gan To Kagaku Ryoho， 2005; 32(4)∶509.
5. 　Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7 [J]. Biochemistry， 2001; 40(4)∶1117.
6. 　Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin [J]. Cancer Res， 2002; 62(9)∶2462.
7. 　Lens SM, Wolthuis RM, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension [J]. EMBO J， 2003; 22(12)∶2934.
8. 　Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions [J]. Drug Resist Updat， 2002; 5(2)∶65.
9. 　Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2 [J]. Clin Cancer Res， 2005; 11(17)∶6382.
10. 　Notarbartolo M, Cervello M, Dusonchet L, et al. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins) [J]. Cancer Lett， 2002; 180(1)∶91.
11. 　韓艷秋， 袁家穎， 石永進， 等. 小檗胺逆轉(zhuǎn)K562/A02細胞耐藥性及其機制 [J]. 中國實驗血液學雜志， 2003; 11(6)∶604.
  1. 1. 　姚學權(quán)， 劉福坤， 祁曉萍， 等. 胃腺癌組織survivin基因的表達與細胞增殖及凋亡的相關(guān)性研究 [J]. 中華外科雜志， 2004； 42（3）∶145.
  2. 2. 　Trieb K, Lehner R, Stulnig T, et al. Survivin expression in human osteosarcoma is a marker for survival [J]. Eur J Surg Oncol， 2003; 29(4)∶379.
  3. 3. 　Chen LT, Liu TW, Wu CW, et al. A phase Ⅰ study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer [J]. Oncology， 2002; 63(3)∶239.
  4. 4. 　Suzuki T, Yoshida K, Tanabe K, et al. Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1 [J]. Gan To Kagaku Ryoho， 2005; 32(4)∶509.
  5. 5. 　Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7 [J]. Biochemistry， 2001; 40(4)∶1117.
  6. 6. 　Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin [J]. Cancer Res， 2002; 62(9)∶2462.
  7. 7. 　Lens SM, Wolthuis RM, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension [J]. EMBO J， 2003; 22(12)∶2934.
  8. 8. 　Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions [J]. Drug Resist Updat， 2002; 5(2)∶65.
  9. 9. 　Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2 [J]. Clin Cancer Res， 2005; 11(17)∶6382.
  10. 10. 　Notarbartolo M, Cervello M, Dusonchet L, et al. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins) [J]. Cancer Lett， 2002; 180(1)∶91.
  11. 11. 　韓艷秋， 袁家穎， 石永進， 等. 小檗胺逆轉(zhuǎn)K562/A02細胞耐藥性及其機制 [J]. 中國實驗血液學雜志， 2003; 11(6)∶604.